Table 2 Patient characteristics of 21 MMR-proficient CRC patients treated with chemotherapy.
TRG | Treatment | Stage | Primary tumor site | |
|---|---|---|---|---|
Patient 1 | 0 | FOLFOX | T3N1aM0 | Rectum |
Patient 2 | 0 | FOLFOX | T4aN2aM0 | Rectum |
Patient 3 | 0 | FOLFOX | T3N0M0 | Rectum |
Patient 4 | 3 | FOLFOX | T3N1aM0 | Rectum |
Patient 5 | 0 | FOLFOX | T4aN2aM1 | Rectum |
Patient 6 | 0 | FOLFOX | T3N2aM0 | Rectum |
Patient 7 | 0 | UNKNOWED | T4aN2bM0 | Rectum |
Patient 8 | 0 | Avastin + FOLFOXIRI | T3N2aM1 | Rectum |
Patient 9 | 3 | FOLFOXIRI | T3N1aM0 | Rectum |
Patient 10 | 3 | FOLFOX | T3N1bM0 | Rectum |
Patient 11 | 0 | FOLFOX | T3N2aM0 | Rectum |
Patient 12 | 3 | FOLFOX | T3N2bM0 | Rectum |
Patient 13 | 3 | FOLFOXIRI | T3N2bM0 | Rectum |
Patient 14 | 0 | FOLFOXIRI | T3N2aM0 | Rectum |
Patient 15 | 3 | FOLFOX | T3N1bM0 | Rectum |
Patient 16 | 3 | FOLFOX | T3N1aM0 | Rectum |
Patient 17 | 3 | XELOX | T4aN2bM1 | Rectum |
Patient 18 | 0 | FOLFOXIRI | T3N1aM0 | Rectum |
Patient 19 | 3 | FOLFOX | T3N0M0 | Rectum |
Patient 20 | 0 | FOLFOX | T3N2bM0 | Rectum |
Patient 21 | 0 | FOLFOXIRI | T3N2aM0 | Rectum |
